Loading…
Triple-Negative Breast Cancer Research and Education Act of 2023
Legislative Progress
Introduced
January 10, 2023
Latest Action
January 20, 2023
Primary Sponsor
Sheila Jackson LeeDemocratic(TX)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
69pct
10d open
vs 10,564 other HR bills in the 118th — cohort avg 68d
Triple-Negative Breast Cancer Research and Education Act of 2023 This bill requires research and education activities related to triple-negative breast cancer. The cells of these breast cancers are negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so they do not respond to hormonal therapy medicines or medicines that target the HER2 protein receptors. Specifically, the National Institutes of Health must conduct and support research into the disease. Additionally, the Centers for Disease Control and Prevention and the Health Resources and Services Administration must develop information about triple-negative breast cancer, including information regarding the elevated risk for minority women, for the public and for health care providers.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2024 · third_quarter · Health Issues
Issues related to Gilead Sciences' drug portfolio. HR 235-Triple Negative Breast Cancer Research & Education.
Client expense: Not reported · Firm income: $50,000
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2024 · second_quarter · Health Issues
Inflation Reduction Act. Issues related to Gilead Sciences' drug portfolio. HR 235-Triple Negative Breast Cancer Research & Education. Clinical trial results for Lenacapavir.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2024 · first_quarter · Health Issues
Inflation Reduction Act. Issues related to Gilead Sciences' drug portfolio. HIV/AIDS funding. HR 235 Triple Negative Breast Cancer Research & Education.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · fourth_quarter · Health Issues
MetastaticBreastCancerAccess to Care Act; HR 8185 - Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act; H.R. 235 - Triple-Negative Breast Cancer Research and Education Act of 2023; H.R. 9565 - Comprehensive Cancer Survivorship Act
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · fourth_quarter · Health Issues
Inflation Reduction Act. Issues related to Gilead Sciences' drug portfolio. HIV/AIDS funding. HR 235 Triple Negative Breast Cancer Research & Education. 340B.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2023 · third_quarter · Health Issues
MetastaticBreastCancerAccess to Care Act; HR 8185 - Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act; H.R. 235 - Triple-Negative Breast Cancer Research and Education Act of 2023; H.R. 9565 - Comprehensive Cancer Survivorship Act
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · third_quarter · Health Issues
Inflation Reduction Act. Issues related to Gilead Sciences' drug portfolio. WH Cancer Moonshot program. HIV/AIDS funding. HR 235, Triple Negative Breast Cancer Research & Education
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2023 · second_quarter · Health Issues
MetastaticBreastCancerAccess to Care Act; HR 8185 - Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act; H.R. 235 - Triple-Negative Breast Cancer Research and Education Act of 2023; H.R. 9565 - Comprehensive Cancer Survivorship Act
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · second_quarter · Health Issues
Inflation Reduction Act. Issues related to Gilead Sciences' drug portfolio. WH Cancer Moonshot program. HIV/AIDS funding. HR 235 Triple Negative Breast Cancer Research & Education
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2023 · first_quarter · Health Issues
MetastaticBreastCancerAccess to Care Act; HR 8185 - Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act; H.R. 235 - Triple-Negative Breast Cancer Research and Education Act of 2023; H.R. 9565 - Comprehensive Cancer Survivorship Act
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| Democratic |
| WI |
| Jared Moskowitz | Democratic | FL |
| Jonathan L. Jackson | Democratic | IL |
| Joseph D. Morelle | Democratic | NY |
| Nikema Williams | Democratic | GA |
| Paul Tonko | Democratic | NY |
| Sheila Cherfilus-McCormick | Democratic | FL |
| Terri A. Sewell | Democratic | AL |
| Troy A. Carter | Democratic | LA |